These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 23142206)

  • 1. Use of F-18 fluorodeoxyglucose positron emission tomography with dual-phase imaging to identify intraductal papillary mucinous neoplasm.
    Saito M; Ishihara T; Tada M; Tsuyuguchi T; Mikata R; Sakai Y; Tawada K; Sugiyama H; Kurosawa J; Otsuka M; Uchida Y; Uchiyama K; Miyazaki M; Yokosuka O
    Clin Gastroenterol Hepatol; 2013 Feb; 11(2):181-6. PubMed ID: 23142206
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Additional value of FDG PET/CT to contrast-enhanced CT in the differentiation between benign and malignant intraductal papillary mucinous neoplasms of the pancreas with mural nodules.
    Takanami K; Hiraide T; Tsuda M; Nakamura Y; Kaneta T; Takase K; Fukuda H; Takahashi S
    Ann Nucl Med; 2011 Aug; 25(7):501-10. PubMed ID: 21537945
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 18-fluorodeoxyglucose positron emission tomography enhances computed tomography diagnosis of malignant intraductal papillary mucinous neoplasms of the pancreas.
    Sperti C; Bissoli S; Pasquali C; Frison L; Liessi G; Chierichetti F; Pedrazzoli S
    Ann Surg; 2007 Dec; 246(6):932-7; discussion 937-9. PubMed ID: 18043094
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of International Consensus Guidelines versus 18-FDG PET in detecting malignancy of intraductal papillary mucinous neoplasms of the pancreas.
    Pedrazzoli S; Sperti C; Pasquali C; Bissoli S; Chierichetti F
    Ann Surg; 2011 Dec; 254(6):971-6. PubMed ID: 22076067
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Does PET with CT Have Clinical Utility in the Management of Patients with Intraductal Papillary Mucinous Neoplasm?
    Roch AM; Barron MR; Tann M; Sandrasegar K; Hannaford KN; Ceppa EP; House MG; Zyromski NJ; Nakeeb A; Schmidt CM
    J Am Coll Surg; 2015 Jul; 221(1):48-56. PubMed ID: 26095551
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Usefulness of positron emission tomography (PET)/contrast-enhanced computed tomography (CE-CT) in discriminating between malignant and benign intraductal papillary mucinous neoplasms (IPMNs).
    Ohta K; Tanada M; Sugawara Y; Teramoto N; Iguchi H
    Pancreatology; 2017; 17(6):911-919. PubMed ID: 29033011
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Single-institution validation of the international consensus guidelines for treatment of branch duct intraductal papillary mucinous neoplasms of the pancreas.
    Nagai K; Doi R; Ito T; Kida A; Koizumi M; Masui T; Kawaguchi Y; Ogawa K; Uemoto S
    J Hepatobiliary Pancreat Surg; 2009; 16(3):353-8. PubMed ID: 19280108
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessment of a Revised Management Strategy for Patients With Intraductal Papillary Mucinous Neoplasms Involving the Main Pancreatic Duct.
    Sugimoto M; Elliott IA; Nguyen AH; Kim S; Muthusamy VR; Watson R; Hines OJ; Dawson DW; Reber HA; Donahue TR
    JAMA Surg; 2017 Jan; 152(1):e163349. PubMed ID: 27829085
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Utility of 2-[18F] fluoro-2-deoxy-D-glucose positron emission tomography in differential diagnosis of benign and malignant intraductal papillary-mucinous neoplasm of the pancreas.
    Tomimaru Y; Takeda Y; Tatsumi M; Kim T; Kobayashi S; Marubashi S; Eguchi H; Tanemura M; Kitagawa T; Nagano H; Umeshita K; Wakasa K; Doki Y; Mori M
    Oncol Rep; 2010 Sep; 24(3):613-20. PubMed ID: 20664965
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Usefulness of dual-phase 18F-FDG PET/CT for diagnosing small pancreatic tumors.
    Kawada N; Uehara H; Hosoki T; Takami M; Shiroeda H; Arisawa T; Tomita Y
    Pancreas; 2015 May; 44(4):655-9. PubMed ID: 25815646
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor-to-blood pool ratio of 18F-fluorodeoxyglucose-positron emission tomography's standardized uptake value as a useful parameter indicating malignant transformation in pancreatic branch-duct intraductal papillary mucinous neoplasm compared to the international Fukuoka guidelines: a retrospective cohort study from surgical resections.
    Suto H; Ando Y; Matsukawa H; Oshima M; Kamada H; Kobara H; Masaki T; Tanaka K; Norikane T; Nishiyama Y; Hirao T; Kumamoto K; Okano K
    HPB (Oxford); 2024 Feb; 26(2):291-298. PubMed ID: 37951806
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intraductal papillary mucinous neoplasms of the pancreas: differentiation of malignant and benign tumors by endoscopic ultrasound findings of mural nodules.
    Ohno E; Hirooka Y; Itoh A; Ishigami M; Katano Y; Ohmiya N; Niwa Y; Goto H
    Ann Surg; 2009 Apr; 249(4):628-34. PubMed ID: 19300203
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Management of branch-duct intraductal papillary mucinous neoplasms: a large single-center study to assess predictors of malignancy and long-term outcomes.
    Ridtitid W; DeWitt JM; Schmidt CM; Roch A; Stuart JS; Sherman S; Al-Haddad MA
    Gastrointest Endosc; 2016 Sep; 84(3):436-45. PubMed ID: 26905937
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pancreatic main-duct involvement in branch-duct IPMNs: an underestimated risk.
    Fritz S; Klauss M; Bergmann F; Strobel O; Schneider L; Werner J; Hackert T; Büchler MW
    Ann Surg; 2014 Nov; 260(5):848-55; discussion 855-6. PubMed ID: 25379856
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diagnostic Accuracy of Preoperative Imaging for Differentiation of Branch Duct Versus Mixed Duct Intraductal Papillary Mucinous Neoplasms.
    Ugbarugba EE; Grieco C; Hart PA; Li F; Sklaw B; Cronley K; Oza VM; Swanson BJ; Walker JP; El-Dika S; Conwell DL; Krishna SG
    Pancreas; 2018; 47(5):556-560. PubMed ID: 29683969
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The utility of F-18 FDG PET/CT in the evaluation of pancreatic intraductal papillary mucinous neoplasm.
    Hong HS; Yun M; Cho A; Choi JY; Kim MJ; Kim KW; Choi YJ; Lee JD
    Clin Nucl Med; 2010 Oct; 35(10):776-9. PubMed ID: 20838285
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Searching for indicators of malignancy in pancreatic intraductal papillary mucinous neoplasms: the value of 18FDG-PET confirmed.
    Baiocchi GL; Bertagna F; Gheza F; Grazioli L; Calanducci D; Giubbini R; Portolani N; Giulini SM
    Ann Surg Oncol; 2012 Oct; 19(11):3574-80. PubMed ID: 22752369
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Value of EUS in early detection of pancreatic ductal adenocarcinomas in patients with intraductal papillary mucinous neoplasms.
    Kamata K; Kitano M; Kudo M; Sakamoto H; Kadosaka K; Miyata T; Imai H; Maekawa K; Chikugo T; Kumano M; Hyodo T; Murakami T; Chiba Y; Takeyama Y
    Endoscopy; 2014 Jan; 46(1):22-9. PubMed ID: 24218310
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Implications of imaging criteria for the management and treatment of intraductal papillary mucinous neoplasms - benign versus malignant findings.
    Walter TC; Steffen IG; Stelter LH; Maurer MH; Bahra M; Faber W; Klein F; Bläker H; Hamm B; Denecke T; Grieser C
    Eur Radiol; 2015 May; 25(5):1329-38. PubMed ID: 25433414
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Endoscopic ultrasonographic findings predict the risk of carcinoma in branch duct intraductal papillary mucinous neoplasms of the pancreas.
    Kobayashi N; Sugimori K; Shimamura T; Hosono K; Watanabe S; Kato S; Ueda M; Endo I; Inayama Y; Maeda S; Nakajima A; Kubota K
    Pancreatology; 2012; 12(2):141-5. PubMed ID: 22487524
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.